← Back to Search

Long-acting Insulin

Insulin Transition Strategies for Type 1 Diabetes (GLIDING Trial)

Phase 4
Waitlist Available
Led By Arthi Thirumalai, MD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours prior to 48 hours after 1st dose of degludec insulin
Awards & highlights

GLIDING Trial Summary

This trial looks at if a bridging dose is needed when switching from one type of insulin to another for people with type 1 diabetes.

Who is the study for?
This trial is for adults aged 18-75 with Type 1 Diabetes, who have been on insulin glargine, can self-monitor blood glucose, and are willing to use a CGM. They must not be pregnant or planning pregnancy soon, undergoing surgery within two weeks, or have certain medical conditions like severe kidney issues or recent heart attacks.Check my eligibility
What is being tested?
The study tests if it's better to switch directly from insulin glargine to degludec (a long-acting insulin) or use a bridging dose of glargine with the first degludec dose. Participants will either get this bridging dose or a placebo alongside their first shot of degludec.See study design
What are the potential side effects?
Possible side effects include low blood sugar levels (hypoglycemia), skin reactions at injection sites, weight gain, swelling in arms and legs, and potential allergic reactions to the insulins used.

GLIDING Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours prior to 48 hours after 1st dose of degludec insulin
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours prior to 48 hours after 1st dose of degludec insulin for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change in Percent Time in Range
Secondary outcome measures
Coefficient of Variation (CV) of Percent-time-in-range
Correction Boluses
Nocturnal Percent Time in Range of 70-180 mg/dL Nocturnal Time in Range (N-TIR)
+4 more

GLIDING Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Insulin Glargine and Insulin DegludecExperimental Treatment2 Interventions
Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
Group II: Insulin Degludec and placeboPlacebo Group2 Interventions
Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Insulin degludec
FDA approved
Insulin glargine
FDA approved

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,739 Previous Clinical Trials
1,847,883 Total Patients Enrolled
Arthi Thirumalai, MDPrincipal Investigator - University of Washington
University of Washington Medical Center

Media Library

Insulin Degludec (Long-acting Insulin) Clinical Trial Eligibility Overview. Trial Name: NCT04623086 — Phase 4
Type 1 Diabetes Research Study Groups: Insulin Glargine and Insulin Degludec, Insulin Degludec and placebo
Type 1 Diabetes Clinical Trial 2023: Insulin Degludec Highlights & Side Effects. Trial Name: NCT04623086 — Phase 4
Insulin Degludec (Long-acting Insulin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04623086 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I meet the eligibility criteria to join this experiment?

"This clinical trial is searching for candidates aged 18-75 with type 1 diabetes to enroll in the study. Approximately 40 people will be accepted into this program."

Answered by AI

Does the research protocol allow for participants who are over twenty years of age?

"The entry requirements for this trial necessitate that potential participants are aged between 18 to 75. There are separate studies with 165 trials designed for those below the age of majority, and an additional 195 trails tailored towards seniors over 65 years old."

Answered by AI

Is recruitment for this clinical trial open at the moment?

"The information posted on clinicaltrials.gov reveals that this study is no longer recruiting new participants, with the post date listed as February 14th 2020 and last update dated May 8th 2023. Nevertheless, there are 398 other trials currently seeking volunteers for their research initiatives."

Answered by AI

To what type of conditions are Insulin Glargine and Insulin Degludec typically recommended?

"Insulin Glargine and Insulin Degludec are typically prescribed to manage hyperglycemia, but they can also be used in combination with liraglutide or regular physical activity for the treatment of type 2 diabetes."

Answered by AI

What potential risks do Insulin Glargine and Insulin Degludec present to users?

"There is existing clinical data demonstrating the safety of Insulin Glargine and Insulin Degludec, so it was assigned a score of 3."

Answered by AI

Is there precedent for concomitantly administering Insulin Glargine and Insulin Degludec?

"Currently, 6 Phase 3 trials are studying both Insulin Glargine and Insulin Degludec. San Francisco is one of the many research cities conducting these investigations; a total of 199 study sites in various locations exist for this purpose."

Answered by AI

How many test subjects are participating in this experiment?

"At present, this trial is no longer open for recruitment. It initially launched on February 14th 2020 and was revised most recently on May 8th 2023. If you are looking for alternative studies, there are 385 clinical trials presently searching for participants with type 1 diabetes as well as 13 trials actively enrolling patients who require Insulin Glargine or Insulin Degludec."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
Arthi Thirumalai 2020. "Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04623086.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top